New insights on the role of the endocannabinoid system in the regulation of energy balance.
Int J Obes. 2015-09-16; 40(2): 210-219
Lire sur PubMed
1. Int J Obes (Lond). 2016 Feb;40(2):210-9. doi: 10.1038/ijo.2015.179. Epub 2015 Sep
New insights on the role of the endocannabinoid system in the regulation of
Gatta-Cherifi B(1)(2)(3), Cota D(1)(2).
(1)INSERM, NeuroCentre Magendie, Physiopathologie de la Plasticité Neuronale,
U862, Bordeaux, France.
(2)University of Bordeaux, Neurocentre Magendie, Physiopathologie de la
Plasticité Neuronale, U862, Bordeaux, France.
(3)Department of Endocrinology, Diabetes and Nutrition, University Hospital of
Bordeaux, Pessac, France.
Within the past 15 years, the endocannabinoid system (ECS) has emerged as a lipid
signaling system critically involved in the regulation of energy balance, as it
exerts a regulatory control on every aspect related to the search, the intake,
the metabolism and the storage of calories. An overactive endocannabinoid
cannabinoid type 1 (CB1) receptor signaling promotes the development of obesity,
insulin resistance and dyslipidemia, representing a valuable pharmacotherapeutic
target for obesity and metabolic disorders. However, because of the psychiatric
side effects, the first generation of brain-penetrant CB1 receptor blockers
developed as antiobesity treatment were removed from the European market in late
2008. Since then, recent studies have identified new mechanisms of action of the
ECS in energy balance and metabolism, as well as novel ways of targeting the
system that may be efficacious for the treatment of obesity and metabolic
disorders. These aspects will be especially highlighted in this review.
PMID: 26374449 [Indexed for MEDLINE]